Infect Chemother.  2020 Jun;52(2):281-304. 10.3947/ic.2020.52.2.281.

Interim Guidelines on Antiviral Therapy for COVID-19

• Kim SB
• Huh K
• Heo JY
• Joo EJ
• Kim YJ
• Choi WS
• Kim YJ
• Seo YB
• Yoon YK
• Ku NS
• Jeong SJ
• Kim SH
• Peck KR
• Yeom JS

• KMID: 2503539
• DOI: http://doi.org/10.3947/ic.2020.52.2.281

Abstract

Since the first case was reported in Wuhan, Hubei Province, China on December 12, 2019, Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January 2020. As of April 16, 2020, 10635 confirmed cases have been reported, with 230 deaths in Korea. COVID-19 patients may be asymptomatic or show various clinical manifestations, including acute symptoms such as fever, fatigue, sore throat; pneumonia presenting as acute respiratory distress syndrome; and multiple organ failure. As COVID-19 has such varied clinical manifestations and case fatality rates, no standard antiviral therapy regimen has been established other than supportive therapy. In the present guideline, we aim to introduce potentially helpful antiviral and other drug therapies based on in vivo and in vitro research and clinical experiences from many countries.

Keyword

COVID-19; SARS-CoV-2; Antiviral; Treatment